MDCC Molecular Devices (MM)

Molecular Devices Announces the Introduction of the IMAP(TM) Progressive Binding System and Nine New Substrates SUNNYVALE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Molecular Devices Corporation , a leader in innovative solutions for drug discovery and life sciences research, today announced the launch of the most recent additions to its IMAP(TM) platform, the IMAP Progressive Binding System and nine new peptide substrates. With the IMAP Progressive Binding System, researchers can achieve enhanced performance for virtually all kinases, phosphatases and phosphodiesterases by addressing key parameters, such as substrate limitations, ATP concentrations and background levels. The nine new peptides added to Molecular Devices' growing line of validated peptides further support IMAP as a complete systems approach for assaying enzyme activity. Molecular Devices' IMAP technology is rapidly becoming the established assay format to screen for kinase and phosphatase activity because it does not rely on radioactivity or antibodies. The new binding system and growing list of validated substrates further enable the end user to develop assays for uncommon or proprietary enzymes with the same ease of miniaturization and low cost-per-well that IMAP users have come to expect. "Kinases and phosphatases are screened at all major pharmaceutical companies, and we believe that IMAP is becoming the preferred screening platform. Molecular Devices will continue to add key components that provide our customers with the flexibility required to address this important yet diverse class of drug targets," stated Stephen Oldfield, Ph.D. and Vice President of Worldwide Marketing at Molecular Devices. "By exploiting the ratiometric format inherent in fluorescence polarization, IMAP leverages Molecular Devices' line of Analyst(R) instruments which are known for setting industry standards in FP detection." Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and combinatorial chemistry by facilitating the high- throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. This press release contains "forward-looking" statements, including statements related to the prospects for the IMAP Progressive Binding System and peptide substrates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2002 and its quarterly report on Form 10-Q for the quarter ended September 30, 2003. Molecular Devices Corporation does not undertake any obligation to update forward- looking statements. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/

Copyright